Earnings season brings clarity—and volatility. Quest Diagnostics (DGX) is in the spotlight after releasing its fourth-quarter and full-year 2025 financial results. DGX reported a 7.1% increase in fourth-quarter revenues, reaching $2.81 billion, compared to 2024. The company's full-year revenue also saw an 11.8% increase from 2024, totaling $11.04 billion. Following the news, DGX saw a modest gain of 0.28%, trading at $191.25.
Lazard (LAZ) also reported its preliminary assets under management (AUM) as of January 31, 2026, totaling approximately $267.0 billion. This includes market appreciation of $7.6 billion and net inflows of $2.9 billion. LAZ shares reacted positively, increasing 0.35% to $57.00. These figures provide a snapshot of the current investment landscape, highlighting areas of growth and investor confidence.
Looking ahead, McDonald's (MCD) is set to release its fourth-quarter earnings on Wednesday morning. Analysts anticipate that the fast-food giant's stock could reach new highs following the results. However, today MCD saw a slight decline of -0.48%, trading at $325.60. Investors will be closely watching to see if McDonald's can meet these high expectations.
AstraZeneca (AZN) also reported its full-year results, showcasing a robust operational performance. However, AZN experienced a decline of -2.60%, trading at $188.01. The mixed reactions across these companies underscore the complexities of earnings season, where positive results don't always translate to immediate stock gains.